Wells Fargo
BGLC icon

Wells Fargo’s BioNexus Gene Lab BGLC Stock Holding History

Wells Fargo’s Portfolio BGLC Stock Details BGLC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$2 – 7302
2026
Q1 		$2 Buy
+1
New +$3 ﹤0.01% 7092

Other funds holding BGLC

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Wells Fargo's BGLC Position: Q2 2026 in Review

Wells Fargo sold out of BioNexus Gene Lab (BGLC) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Wells Fargo first reported a position in BGLC in Q1 2026 and held it in 1 quarter. The position peaked at $2 in Q1 2026. 3 funds tracked by Wall St. Rank hold BGLC as of Q2 2026.

  • Wells Fargo reported no remaining BioNexus Gene Lab position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 1 BioNexus Gene Lab share in Q2 2026, an estimated $2.
  • Wells Fargo first reported a position in BioNexus Gene Lab in Q1 2026 and held it in 1 quarter.
  • Wells Fargo's BioNexus Gene Lab position peaked at $2 in Q1 2026.
  • 3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.